Development of order-made therapy for pancreatic cancer controlling of crosstalk between cancer cell and cancer associated fibroblast
| Project/Area Number |
16K10588
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Motoi Fuyuhiko 東北大学, 医学系研究科, 准教授 (30343057)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
立川 正憲 徳島大学, 大学院医歯薬学研究部(薬学域), 教授 (00401810)
大塚 英郎 東北大学, 大学病院, 助教 (50451563)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2018: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 膵癌 / 癌 / 抗癌剤 |
|---|
| Outline of Final Research Achievements |
Platelet-derived growth factor receptor beta (PDGFRβ) and hepatocyte growth factor receptor (MET) expressed on cancer-associated fibroblast (CAFs) are suggested as important components modulating the interactions between pancreatic cancer cells (PCCs) and CAFs. The objective of this study is to clarify the effect of MK2461, a multikinase inhibitor targeting MET and PDGFRβ, on the interaction between PCCs and CAFs. In CAFs, PDGFRβ and MET were upregulated compared with other receptor tyrosine kinases. Conditioned medium from CAFs promoted the proliferation of PCCs, and vice versa. Moreover, MK2461 suppressed the effects of conditioned medium on PCCs and CAFs. Finally, MK2461 significantly inhibited tumor growth in mice coinjected with PCCs and CAFs.
The PDGFRβ and MET may play a critical role in the interaction between PCCs and CAFs, which was modulated by MK2461. Therefore, MK2461 may have therapeutic potential in the treatment of pancreatic cancer.
|
| Academic Significance and Societal Importance of the Research Achievements |
膵癌は有効な治療法が少なく、難治性癌の代表である。既存薬以外の治療標的を見出すことで、有効薬の創薬につながる可能性がある膵癌と癌関連線維芽細胞に着目した治療戦略は、膵癌治療に重要な役割を果たす可能性が示唆され、これらの経路を制御することで、特異的な治療戦略の開発が期待出来る。代表的難治癌の治療成績向上につながれば、学術的・社会的意義がある。
|
Report
(4 results)
Research Products
(12 results)
-
[Journal Article] Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma.2019
Author(s)
Motoi F, Murakami Y, Okada KI, Matsumoto I, Uemura K, Satoi S, Sho M, Honda G, Fukumoto T, Yanagimoto H, Kinoshita S, Kurata M, Aoki S, Mizuma M, Yamaue H, Unno M; Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS).
-
Journal Title
World J Surg.
Volume: 43
Issue: 2
Pages: 634-641
DOI
Related Report
Peer Reviewed
-
[Journal Article] Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.2019
Author(s)
Aoki S, Motoi F, Murakami Y, Sho M, Satoi S, Honda G, Uemura K, Okada KI, Matsumoto I, Nagai M, Yanagimoto H, Kurata M, Fukumoto T, Mizuma M, Yamaue H, Unno M; Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS).
-
Journal Title
BMC Cancer.
Volume: 19
Issue: 1
Pages: 252-252
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
[Journal Article] 切除不能膵癌に対するGemcitabine+Nab-Paclitaxel療法を用いた集学的治療2017
Author(s)
元井 冬彦, 高舘 達之, 前田 晋平, 有明 恭平, 益田 邦洋, 石田 晶玄, 深瀬 耕二, 水間 正道, 大塚 英郎, 坂田 直昭, 林 洋毅, 中川 圭, 森川 孝則, 内藤 剛, 海野 倫明
-
Journal Title
癌と化学療法
Volume: 44
Pages: 1241-1244
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
